1 week Ago By Defense World Staff
Puma Biotechnology, Inc. ( NASDAQ:PBYI – Free Report ) – Stock analysts at Zacks Research raised their Q4 2025 earnings per share estimates for Puma Biotechnology in a research note issued on Wednesday, January 22nd. Zacks Research analyst R.
Department now anticipates that the biopharmaceutical company will post earnings per share of $0.16 for the quarter, up from their previous estimate of $0.13.
The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q2 2026 earnings at $0.
01 EPS and Q3 2026 earnings at $0.11 EPS. A number of other research firms also recently weighed in on PBYI.
StockNews.com downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 6th. HC Wainwright reaffirmed a “buy” rating and set a $7.
00 price objective on shares of Puma Biotechnology in a report on Monday, December 23rd. Puma Biotechnology Trading Down 2.0 % Shares of PBYI opened at $2.
96 on Friday. The stock’s 50-day moving average price is $3.06 and its 200 day moving average price is $2.
99. The company has a quick ratio of 1.40, a current ratio of 1.
42 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $145.
31 million, a price-to-earnings ratio of 6.17 and a beta of 1.10.
Puma Biotechnology has a 12-month low of $2.22 and a 12-month high of $7.73.
Puma Biotechnology ( NASDAQ:PBYI – Get Free Report ) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.
31 by $0.10. The company had revenue of $80.
50 million during the quarter, compared to analysts’ expectations of $71.32 million. Puma Biotechnology had a return on equity of 41.
60% and a net margin of 9.56%. During the same period in the prior year, the business earned $0.
12 earnings per share. Institutional Inflows and Outflows Several hedge funds have recently modified their holdings of the business. Patriot Financial Group Insurance Agency LLC lifted its holdings in Puma Biotechnology by 72.
7% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 8,000 shares during the period. Royce & Associates LP lifted its stake in shares of Puma Biotechnology by 71.
8% in the 3rd quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 8,427 shares during the period. Gateway Wealth Partners LLC acquired a new position in shares of Puma Biotechnology in the 4th quarter valued at $31,000.
Squarepoint Ops LLC boosted its position in shares of Puma Biotechnology by 17.7% in the 2nd quarter. Squarepoint Ops LLC now owns 71,391 shares of the biopharmaceutical company’s stock worth $233,000 after purchasing an additional 10,757 shares during the last quarter.
Finally, SG Americas Securities LLC grew its stake in shares of Puma Biotechnology by 83.9% during the fourth quarter. SG Americas Securities LLC now owns 24,668 shares of the biopharmaceutical company’s stock worth $75,000 after purchasing an additional 11,252 shares during the period.
Institutional investors own 61.29% of the company’s stock. Insider Buying and Selling at Puma Biotechnology In related news, insider Jeffrey Jerome Ludwig sold 9,437 shares of the firm’s stock in a transaction dated Thursday, January 2nd.
The stock was sold at an average price of $3.15, for a total value of $29,726.55.
Following the transaction, the insider now owns 108,951 shares in the company, valued at $343,195.65. This trade represents a 7.
97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website . Also, CEO Alan H.
Auerbach sold 33,841 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $106,599.
15. Following the sale, the chief executive officer now directly owns 7,029,674 shares of the company’s stock, valued at $22,143,473.10.
This represents a 0.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
Corporate insiders own 23.70% of the company’s stock. Puma Biotechnology Company Profile ( Get Free Report ) Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. Recommended Stories Five stocks we like better than Puma Biotechnology Stock Market Sectors: What Are They and How Many Are There? Bloom Energy: Powering the Future With Decentralized Energy How Investors Can Identify and Successfully Trade Gap-Down Stocks Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul NYSE Stocks Give Investors a Variety of Quality Options Why Traders Are Buying the Dip on Johnson & Johnson Stock Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter .
.
